Trial Profile
A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Cantharidin (Primary)
- Indications Warts
- Focus Therapeutic Use
- Acronyms COVE-1
- Sponsors Verrica Pharmaceuticals
- 18 Oct 2019 According to a Verrica Pharmaceuticals media release, data are being presented at the 2019 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV.
- 18 Oct 2019 According to a Verrica Pharmaceuticals media release, company is planning to meet with the FDA to determine next steps on the development of VP-102 for common warts following positive Phase 2 results.
- 18 Oct 2019 Results presented in a Verrica Pharmaceuticals Media Release.